Sigilon Therapeutics P/E Ratio

Sigilon Therapeutics (SGTX) currently reports a P/E ratio of -16.77. That is below the Healthcare sector average of 27.28. Use the charts on this page to explore Sigilon Therapeutics's P/E ratio history and peer comparisons.

Sigilon Therapeutics's P/E ratio of -16.77 is lower than the Healthcare sector average of 27.28. That is roughly 161.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Sigilon Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -16.77, SGTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -16.77, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.28. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.

Sigilon Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -16.77 versus a sector average near 27.28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGTX with unrelated industries.